David A. Siegel Biocryst Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 4,228,412 shares of BCRX stock, worth $28.4 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
4,228,412
Previous 3,220,712
31.29%
Holding current value
$28.4 Million
Previous $24.2 Million
56.85%
% of portfolio
0.08%
Previous 0.06%
Shares
32 transactions
Others Institutions Holding BCRX
# of Institutions
315Shares Held
201MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$138 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$134 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$57.2 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$56.9 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$38.4 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.25B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...